175 related articles for article (PubMed ID: 37715125)
1. Value of Echocardiography and Cardiac Magnetic resonance in assessing left ventricular function in breast and gastric cancer patients after Anthracycline Chemotherapy.
Jin CL; Shi XG; Wang TT; Li HW; Zhang DX; Sheng Z; Xiao J; Yu YQ
BMC Cardiovasc Disord; 2023 Sep; 23(1):465. PubMed ID: 37715125
[TBL] [Abstract][Full Text] [Related]
2. Two-dimensional speckle tracking echocardiography, a powerful method for the evaluation of anthracyclines induced left ventricular insufficiency.
Chen W; Jiao Z; Li W; Han R
Medicine (Baltimore); 2022 Oct; 101(42):e31084. PubMed ID: 36281099
[TBL] [Abstract][Full Text] [Related]
3. Early detection of anthracycline- and trastuzumab-induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters.
Díaz-Antón B; Madurga R; Zorita B; Wasniewski S; Moreno-Arciniegas A; López-Melgar B; Ramírez Merino N; Martín-Asenjo R; Barrio P; Amado Escañuela MG; Solís J; Parra Jiménez FJ; Ciruelos E; Castellano JM; Fernández-Friera L
ESC Heart Fail; 2022 Apr; 9(2):1127-1137. PubMed ID: 35106939
[TBL] [Abstract][Full Text] [Related]
4. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.
Drafts BC; Twomley KM; D'Agostino R; Lawrence J; Avis N; Ellis LR; Thohan V; Jordan J; Melin SA; Torti FM; Little WC; Hamilton CA; Hundley WG
JACC Cardiovasc Imaging; 2013 Aug; 6(8):877-85. PubMed ID: 23643285
[TBL] [Abstract][Full Text] [Related]
5. Early anthracycline-induced cardiotoxicity monitored by echocardiographic Doppler parameters combined with serum hs-cTnT.
Zhang CJ; Pei XL; Song FY; Guo Y; Zhang QL; Shu XH; Hsi DH; Cheng LL
Echocardiography; 2017 Nov; 34(11):1593-1600. PubMed ID: 28942608
[TBL] [Abstract][Full Text] [Related]
6. [Early detection of the cardiotoxicity induced by chemotherapy drug through two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T].
Wang W; Kang Y; Shu XH; Shen XD; He B
Zhonghua Zhong Liu Za Zhi; 2017 Nov; 39(11):835-840. PubMed ID: 29151290
[No Abstract] [Full Text] [Related]
7. Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.
Henriksen PA; Hall P; MacPherson IR; Joshi SS; Singh T; Maclean M; Lewis S; Rodriguez A; Fletcher A; Everett RJ; Stavert H; Broom A; Eddie L; Primrose L; McVicars H; McKay P; Borley A; Rowntree C; Lord S; Collins G; Radford J; Guppy A; Williams MC; Japp A; Payne JR; Newby DE; Mills NL; Oikonomidou O; Lang NN
Circulation; 2023 Nov; 148(21):1680-1690. PubMed ID: 37746692
[TBL] [Abstract][Full Text] [Related]
8. Three-Dimensional Speckle-Tracking Echocardiography to Evaluate Left Ventricular Function of Patients with Breast Cancer After Anthracycline Chemotherapy.
Lu S; Sun Y; Li Q; Liu Y; Cui H; Liang X
Altern Ther Health Med; 2023 Oct; 29(7):388-393. PubMed ID: 37535910
[TBL] [Abstract][Full Text] [Related]
9. Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity.
Henriksen PA; Hall P; Oikonomidou O; MacPherson IR; Maclean M; Lewis S; McVicars H; Broom A; Scott F; McKay P; Borley A; Rowntree C; Lord S; Collins G; Radford J; Guppy A; Payne JR; Newby DE; Mills NL; Lang NN
Circ Heart Fail; 2022 Jul; 15(7):e009445. PubMed ID: 35766037
[TBL] [Abstract][Full Text] [Related]
10. Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months.
Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Byth K; Stuart K; Clarke JL; Thomas L
Eur J Cancer; 2013 Nov; 49(16):3396-403. PubMed ID: 23937961
[TBL] [Abstract][Full Text] [Related]
11. Validating real-time three-dimensional echocardiography against cardiac magnetic resonance, for the determination of ventricular mass, volume and ejection fraction: a meta-analysis.
Dissabandara T; Lin K; Forwood M; Sun J
Clin Res Cardiol; 2024 Mar; 113(3):367-392. PubMed ID: 37079054
[TBL] [Abstract][Full Text] [Related]
12. Early detection of cardiotoxicity by 3D speckle tracking imaging of area strain in breast cancer patients receiving chemotherapy.
Chen J; Wang L; Wu FF; Sun G
Echocardiography; 2019 Sep; 36(9):1682-1688. PubMed ID: 31503352
[TBL] [Abstract][Full Text] [Related]
13. 2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility.
Santoro C; Arpino G; Esposito R; Lembo M; Paciolla I; Cardalesi C; de Simone G; Trimarco B; De Placido S; Galderisi M
Eur Heart J Cardiovasc Imaging; 2017 May; 18(8):930-936. PubMed ID: 28379383
[TBL] [Abstract][Full Text] [Related]
14. Are Biomarkers Predictive of Anthracycline-Induced Cardiac Dysfunction?
Malik A; Jeyaraj PA; Calton R; Uppal B; Negi P; Shankar A; Patil J; Mahajan MK
Asian Pac J Cancer Prev; 2016; 17(4):2301-5. PubMed ID: 27221934
[TBL] [Abstract][Full Text] [Related]
15. Assessing the cardiotoxicity of Epirubicin-based chemotherapy in patients with breast cancer using high-sensitivity cardiac troponin T, N-terminal pro b-type natriuretic peptide and soluble suppression of tumorigenicity-2.
Isemede DA; Sharma A; Bailey J
Ann Clin Biochem; 2022 Nov; 59(6):410-419. PubMed ID: 36154484
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonance.
Jordan JH; D'Agostino RB; Hamilton CA; Vasu S; Hall ME; Kitzman DW; Thohan V; Lawrence JA; Ellis LR; Lash TL; Hundley WG
Circ Cardiovasc Imaging; 2014 Nov; 7(6):872-9. PubMed ID: 25273568
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Cardiac Biomarkers Assessment in Combination with Myocardial 2D Strain Echocardiography for Early Detection of Anthracycline-Related Cardiac Toxicity.
Mahjoob MP; Sheikholeslami SA; Dadras M; Mansouri H; Haghi M; Naderian M; Sadeghi L; Tabary M; Khaheshi I
Cardiovasc Hematol Disord Drug Targets; 2020; 20(1):74-83. PubMed ID: 31513000
[TBL] [Abstract][Full Text] [Related]
18. Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50-59% treated with anthracyclines.
Mousavi N; Tan TC; Ali M; Halpern EF; Wang L; Scherrer-Crosbie M
Eur Heart J Cardiovasc Imaging; 2015 Sep; 16(9):977-84. PubMed ID: 25925220
[TBL] [Abstract][Full Text] [Related]
19. High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients.
Kitayama H; Kondo T; Sugiyama J; Kurimoto K; Nishino Y; Kawada M; Hirayama M; Tsuji Y
Breast Cancer; 2017 Nov; 24(6):774-782. PubMed ID: 28434150
[TBL] [Abstract][Full Text] [Related]
20. Role of Statin Therapy in Prevention of Anthracycline-Induced Cardiotoxicity: A Three Dimentional Echocardiography Study.
Mohamed AL; El-Abd AA; Mohamed HG; Noufal AM; Hennawy BS
Curr Probl Cardiol; 2024 Jan; 49(1 Pt C):102130. PubMed ID: 37858847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
